What is Orgenesis?
Orgenesis operates as a global biotechnology enterprise dedicated to democratizing access to complex cell and gene therapies. At the core of its business model is the proprietary POCare Platform, a sophisticated ecosystem designed to facilitate the production of therapeutics at the point of care. By integrating automated technology systems with a collaborative network of clinical partners, research institutions, and healthcare providers, the company effectively addresses the logistical and financial barriers traditionally associated with CGT manufacturing. This decentralized framework allows for the rapid, scalable, and cost-efficient delivery of life-saving treatments, positioning Orgenesis as a transformative force in modern medicine.
The company's operational strategy relies on a three-pronged approach: identifying high-potential therapeutic candidates, utilizing closed-loop automated production technologies, and fostering a global network of clinical sites. This harmonized pathway ensures that innovative therapies can be developed and administered in a regulated, efficient manner, ultimately expanding patient access to personalized medicine on a global scale.
How much funding has Orgenesis raised?
Orgenesis has raised a total of $55M across 2 funding rounds:
Unspecified
$50M
Private Equity
$5M
Unspecified (2022): $50M with participation from Metalmark Capital
Private Equity (2023): $5M led by Metalmark Capital Partners
Key Investors in Orgenesis
Metalmark Capital
Metalmark Capital is a growth equity investment firm that focuses on founder-owned businesses in the middle market, aiming to build long-term value through active and collaborative partnerships.
Metalmark Capital Partners
An affiliate of Metalmark Capital, this entity focuses on strategic capital deployment to support the scaling of high-growth enterprises in the healthcare and biotech sectors.
What's next for Orgenesis?
With the recent influx of capital, Orgenesis is well-positioned to accelerate the expansion of its POCare Network and further refine its automated production technologies. The company's strategic roadmap likely involves scaling its clinical development pipeline and deepening its collaborative partnerships with hospitals and research centers worldwide. As the biotech industry shifts toward decentralized manufacturing models, Orgenesis is poised to capitalize on the increasing demand for affordable, point-of-care therapeutic solutions. Future growth will likely be driven by the successful commercialization of its licensed therapeutics and the continued optimization of its global production infrastructure, ensuring that the company remains at the forefront of the next generation of healthcare delivery.
See full Orgenesis company page
